Your browser doesn't support javascript.
loading
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Villablanca, Judith G; London, Wendy B; Naranjo, Arlene; McGrady, Patrick; Ames, Matthew M; Reid, Joel M; McGovern, Renee M; Buhrow, Sarah A; Jackson, Hollie; Stranzinger, Enno; Kitchen, Brenda J; Sondel, Paul M; Parisi, Marguerite T; Shulkin, Barry; Yanik, Gregory A; Cohn, Susan L; Reynolds, C Patrick.
Afiliação
  • Villablanca JG; Children's Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA. jvillablanca@chla.usc.edu
Clin Cancer Res ; 17(21): 6858-66, 2011 Nov 01.
Article em En | MEDLINE | ID: mdl-21908574

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenretinida / Recidiva Local de Neoplasia / Neuroblastoma / Antineoplásicos Idioma: En Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenretinida / Recidiva Local de Neoplasia / Neuroblastoma / Antineoplásicos Idioma: En Ano de publicação: 2011 Tipo de documento: Article